TY - JOUR
T1 - The Landscape of Immunotherapy for Retroperitoneal Sarcoma
AU - Gingrich, Alicia A.
AU - Nassif, Elise F.
AU - Roland, Christina L.
AU - Keung, Emily Z.
N1 - Publisher Copyright:
© 2023 by the authors.
PY - 2023/2
Y1 - 2023/2
N2 - Significant multidisciplinary scientific effort has been undertaken to understand the heterogeneous family of neoplasms that comprise soft tissue sarcomas. Within this family of neoplasms, outcomes for retroperitoneal sarcomas (RPS) are currently limited given a lack of effective therapies. In this review, we focus on immunotherapy and its relationship with the common RPS histologic subtypes. Although initial outcomes for RPS patients with immune checkpoint inhibition alone have been somewhat disappointing, subsequent analyses on histologies, the tumor microenvironment, sarcoma immune class, tumor infiltrating lymphocytes and genetic analysis for tumor mutational burden have yielded insight into the interplay between sarcomas and immunotherapy. Such approaches have all provided critical insight into the environment and characterization of these tumors, with targets for potential immunotherapy in future clinical trials. With this insight, molecularly tailored combination treatments for improving response rates and oncologic outcomes for RPS are promising.
AB - Significant multidisciplinary scientific effort has been undertaken to understand the heterogeneous family of neoplasms that comprise soft tissue sarcomas. Within this family of neoplasms, outcomes for retroperitoneal sarcomas (RPS) are currently limited given a lack of effective therapies. In this review, we focus on immunotherapy and its relationship with the common RPS histologic subtypes. Although initial outcomes for RPS patients with immune checkpoint inhibition alone have been somewhat disappointing, subsequent analyses on histologies, the tumor microenvironment, sarcoma immune class, tumor infiltrating lymphocytes and genetic analysis for tumor mutational burden have yielded insight into the interplay between sarcomas and immunotherapy. Such approaches have all provided critical insight into the environment and characterization of these tumors, with targets for potential immunotherapy in future clinical trials. With this insight, molecularly tailored combination treatments for improving response rates and oncologic outcomes for RPS are promising.
KW - immunotherapy
KW - retroperitoneal sarcoma
KW - sarcoma immune class
KW - tumor infiltrating lymphocyte
KW - tumor microenvironment
KW - tumor mutational burden
UR - http://www.scopus.com/inward/record.url?scp=85148756367&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85148756367&partnerID=8YFLogxK
U2 - 10.3390/curroncol30020165
DO - 10.3390/curroncol30020165
M3 - Review article
C2 - 36826126
AN - SCOPUS:85148756367
SN - 1198-0052
VL - 30
SP - 2144
EP - 2158
JO - Current Oncology
JF - Current Oncology
IS - 2
ER -